X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (25666) 25666
Newsletter (379) 379
Newspaper Article (103) 103
Magazine Article (58) 58
Book Chapter (45) 45
Dissertation (30) 30
Conference Proceeding (9) 9
Publication (9) 9
Transcript (6) 6
Streaming Video (5) 5
Web Resource (3) 3
Reference (2) 2
Trade Publication Article (2) 2
Book / eBook (1) 1
Book Review (1) 1
Government Document (1) 1
Journal / eJournal (1) 1
Report (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (21410) 21410
male (12912) 12912
female (12904) 12904
vincristine - administration & dosage (11880) 11880
science & technology (11496) 11496
antineoplastic combined chemotherapy protocols - therapeutic use (11393) 11393
life sciences & biomedicine (11301) 11301
middle aged (8763) 8763
adult (8396) 8396
cyclophosphamide - administration & dosage (7570) 7570
vincristine - therapeutic use (7371) 7371
doxorubicin - administration & dosage (6814) 6814
aged (6398) 6398
oncology (5955) 5955
prednisone - administration & dosage (5322) 5322
vincristine (5019) 5019
adolescent (4505) 4505
cyclophosphamide - therapeutic use (4346) 4346
child (3761) 3761
chemotherapy (3646) 3646
prednisone - therapeutic use (3571) 3571
antineoplastic combined chemotherapy protocols - administration & dosage (3556) 3556
treatment outcome (3404) 3404
hematology (3399) 3399
combined modality therapy (3393) 3393
prognosis (3345) 3345
doxorubicin - therapeutic use (3232) 3232
vincristine - adverse effects (3013) 3013
animals (2868) 2868
abridged index medicus (2865) 2865
antineoplastic combined chemotherapy protocols - adverse effects (2848) 2848
child, preschool (2832) 2832
methotrexate - administration & dosage (2547) 2547
vincristine - pharmacology (2517) 2517
cancer (2489) 2489
drug therapy, combination (2486) 2486
remission induction (2155) 2155
etoposide - administration & dosage (2094) 2094
lymphoma, large b-cell, diffuse - drug therapy (1918) 1918
follow-up studies (1896) 1896
retrospective studies (1867) 1867
lymphoma, non-hodgkin - drug therapy (1856) 1856
neoplasm staging (1856) 1856
bleomycin - administration & dosage (1847) 1847
infant (1843) 1843
time factors (1754) 1754
rituximab (1730) 1730
disease-free survival (1681) 1681
hodgkin disease - drug therapy (1658) 1658
lymphomas (1638) 1638
antineoplastic agents - therapeutic use (1612) 1612
survival rate (1580) 1580
cyclophosphamide - adverse effects (1557) 1557
procarbazine - administration & dosage (1508) 1508
aged, 80 and over (1487) 1487
methotrexate - therapeutic use (1462) 1462
drug administration schedule (1426) 1426
doxorubicin - adverse effects (1424) 1424
prednisolone - administration & dosage (1410) 1410
mice (1379) 1379
cyclophosphamide (1364) 1364
care and treatment (1335) 1335
survival analysis (1328) 1328
prednisone - adverse effects (1258) 1258
pediatrics (1233) 1233
doxorubicin (1216) 1216
cytarabine - administration & dosage (1209) 1209
cisplatin - administration & dosage (1201) 1201
antineoplastic agents - administration & dosage (1100) 1100
antineoplastic combined chemotherapy protocols (1055) 1055
lung neoplasms - drug therapy (1007) 1007
clinical trials as topic (999) 999
dose-response relationship, drug (965) 965
dactinomycin - administration & dosage (964) 964
drug resistance (963) 963
young adult (961) 961
research (950) 950
precursor cell lymphoblastic leukemia-lymphoma - drug therapy (941) 941
prospective studies (940) 940
dexamethasone - administration & dosage (933) 933
lymphoma - drug therapy (921) 921
lymphoma, large b-cell, diffuse - pathology (905) 905
leukemia, lymphoid - drug therapy (867) 867
antineoplastic agents - pharmacology (862) 862
antibodies, monoclonal, murine-derived (856) 856
recurrence (839) 839
risk factors (832) 832
lymphoma (825) 825
medicine & public health (821) 821
pharmacology & pharmacy (819) 819
prednisone (819) 819
neoplasm metastasis (813) 813
dacarbazine - administration & dosage (784) 784
procarbazine - therapeutic use (766) 766
mechlorethamine - administration & dosage (765) 765
remission, spontaneous (758) 758
analysis (753) 753
patients (721) 721
radiotherapy (718) 718
breast neoplasms - drug therapy (708) 708
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (22769) 22769
Japanese (1275) 1275
German (827) 827
French (564) 564
Chinese (481) 481
Spanish (340) 340
Russian (319) 319
Italian (238) 238
Polish (236) 236
Portuguese (78) 78
Dutch (36) 36
Hungarian (32) 32
Danish (23) 23
Hebrew (21) 21
Czech (16) 16
Korean (15) 15
Croatian (12) 12
Serbian (12) 12
Swedish (10) 10
Turkish (9) 9
Norwegian (8) 8
Romanian (8) 8
Ukrainian (7) 7
Bulgarian (5) 5
Finnish (5) 5
Slovak (4) 4
Arabic (2) 2
Lithuanian (2) 2
Bosnian (1) 1
Icelandic (1) 1
Persian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
The lancet oncology, ISSN 1470-2045, 02/2012, Volume 13, Issue 2, pp. 196 - 206
Summary Background Post-transplantation lymphoproliferative disorder (PTLD) develops in 1–10% of transplant recipients and can be Epstein–Barr virus (EBV)... 
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Doxorubicin - therapeutic use | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prednisolone - administration & dosage | Prospective Studies | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Male | Organ Transplantation - pathology | Cyclophosphamide - therapeutic use | Epstein-Barr Virus Infections - therapy | Vincristine - administration & dosage | Adult | Female | Herpesvirus 4, Human - pathogenicity | Prednisolone - therapeutic use | France | Lymphoproliferative Disorders - etiology | Doxorubicin - administration & dosage | Antigens, CD20 - immunology | Rituximab | Lymphoproliferative Disorders - pathology | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Organ Transplantation - adverse effects | Adolescent | Vincristine - therapeutic use | Epstein-Barr Virus Infections - diagnosis | Lymphoproliferative Disorders - drug therapy | Aged | Germany | Antibodies, Monoclonal, Murine-Derived - therapeutic use | Anthracyclines | Cyclophosphamide | Chemotherapy | Corticosteroids | Organ transplant recipients | Clinical trials | Product development | Epstein-Barr virus | Universities and colleges | Prednisolone | Cancer | Index Medicus | Antibodies, Monoclonal, Murine-Derived | Antigens, CD20 | Lymphoproliferative Disorders | Antineoplastic Combined Chemotherapy Protocols | Organ Transplantation | Vincristine | Doxorubicin | Herpesvirus 4, Human | Life Sciences | Immunology | Epstein-Barr Virus Infections
Journal Article
The New England journal of medicine, ISSN 1533-4406, 08/2012, Volume 367, Issue 6, pp. 520 - 531
This international prospective study showed that maintenance therapy with rituximab was more effective than interferon alfa in prolonging the duration of... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Doxorubicin - therapeutic use | Cyclophosphamide - administration & dosage | Prospective Studies | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Induction Chemotherapy | Male | Cyclophosphamide - adverse effects | Cyclophosphamide - therapeutic use | Lymphoma, Mantle-Cell - mortality | Aged, 80 and over | Female | Maintenance Chemotherapy | Prednisone - adverse effects | Lymphoma, Mantle-Cell - drug therapy | Rituximab | Survival Rate | Vidarabine - analogs & derivatives | Remission Induction | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Intention to Treat Analysis | Vincristine - therapeutic use | Vincristine - adverse effects | Aged | Vidarabine - administration & dosage | Antibodies, Monoclonal, Murine-Derived - adverse effects | Doxorubicin - adverse effects | Prednisone - therapeutic use | Antibodies, Monoclonal, Murine-Derived - therapeutic use | Drugs | Dose-response relationship (Biochemistry) | Care and treatment | Fludarabine | Mantle cell lymphoma | Aged patients | Dosage and administration | Product/Service Evaluations | Drug therapy | Health aspects | Clinical trials | Prednisone | Lymphoma | Doxorubicin | Patients | Vincristine | α-Interferon | Cyclophosphamide | Motivation | Remission | Lymphomas | Computer centers | Age | Index Medicus | Abridged Index Medicus
Journal Article
Journal Article
The New England journal of medicine, ISSN 1533-4406, 04/2013, Volume 368, Issue 15, pp. 1408 - 1416
A dose-intense infusional chemotherapy program plus rituximab had a high degree of efficacy in patients with primary mediastinal B-cell lymphoma, which is... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Follow-Up Studies | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Cyclophosphamide - adverse effects | Filgrastim | Dose-Response Relationship, Drug | Young Adult | Vincristine - administration & dosage | Adult | Female | Retrospective Studies | Doxorubicin - administration & dosage | Prednisone - administration & dosage | Etoposide - adverse effects | Lymphoma, Large B-Cell, Diffuse - drug therapy | Prednisone - adverse effects | Kaplan-Meier Estimate | Rituximab | Stroke Volume - drug effects | Etoposide - administration & dosage | Recombinant Proteins - administration & dosage | Disease-Free Survival | Vincristine - adverse effects | Aged | Antibodies, Monoclonal, Murine-Derived - adverse effects | Doxorubicin - adverse effects | Granulocyte Colony-Stimulating Factor - administration & dosage | Drugs | Dose-response relationship (Biochemistry) | Usage | Cyclophosphamide | Patient outcomes | Dosage and administration | Lymphomas | Product/Service Evaluations | Drug therapy, Combination | Drug therapy | Doxorubicin | Medical research | Nuclear magnetic resonance--NMR | Disease | Review boards | Genes | Etoposide | Prednisone | Radiation therapy | Kinases | Vincristine | Patients | Morbidity | Chemotherapy | Lymphocytes B | Remission | Mutation | Hodgkin's disease | B-cell lymphoma | Index Medicus | Abridged Index Medicus
Journal Article
The New England journal of medicine, ISSN 1533-4406, 11/2013, Volume 369, Issue 20, pp. 1915 - 1925
Journal Article